Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1652)

COMPLETION OF TRAINING FOR DIRECTORS

Reference is made to the statement of disciplinary action (the "Statement") published by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") dated 4 January 2023, in relation to, among other things, the sanctions and directions imposed on Fusen Pharmaceutical Company Limited (the "Company") and the relevant directors of the Company, being Mr. Cao Changcheng, Mr. Cao Zhiming, Mr. Chi Yongsheng, Mr. Hou Taisheng and Ms. Meng Qingfen (collectively, the "Relevant Directors").

As stated in the Statement, the Listing Committee of the Stock Exchange has directed, among other things, that each of the Relevant Directors attend 24 hours of training on regulatory and legal topics including compliance with the Rules Governing the Listing of Securities on the Stock Exchange (the "**Training**").

The Company confirms that each of the Relevant Directors had completed the Training and the written certification of full compliance with the Training requirement has been provided to the Stock Exchange.

By order of the Board
Fusen Pharmaceutical Company Limited
Cao Changcheng

Chairman and Executive Director

Hong Kong, 28 March 2023

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming (formerly known as Mr. Cao Dudu) as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.